Watching social media in real time, AI could help change vaccine skeptics’ minds

AI analysis of social media posts can help gauge levels of public trust in, and skepticism of, COVID vaccination programs. Armed with such insights, local and national influencers could tailor promotional campaigns and policy interventions to boost vaccine buy-in.

So conclude researchers who applied natural language processing to tease out underlying attitudes and concerns behind more than 300,000 comments posted in 2020 by Facebook and Twitter users in the U.S. and U.K.

Combined, the two countries’ posters averaged 57% positive, 23% negative and 17.5% neutral sentiments toward COVID inoculation.

The authors stress that the project’s key achievement was demonstrating “the potential of AI-enabled real-time social media monitoring of public sentiments and attitudes to help detect and prevent [vaccine] fears and also to enable policymakers to understand the reasons why some social groups may be reluctant to be vaccinated against COVID-19.”

Such AI analyses, they add, “could enable real-time assessment, at scale, of public confidence and trust in COVID-19 vaccines, help address the concerns of vaccine skeptics, and help develop more effective policies and communication strategies to maximize uptake.”

The study was led by Amir Hussain, PhD, of Edinburgh Napier University. Senior author was Aziz Sheikh, MBBS, of the University of Edinburgh. Contributing from the U.S. was Azhar Ali, MBA, MBBS, of Harvard.

The Journal of Medical Internet Research published the work and has posted it in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.